Loading…
Scilex Holding Company is projected to decline to $6.37 by 2027, a -6% move from its current price of $6.81. SCLX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.44 | $6.81 | $7.21 | +0.06% |
| May 30 | $6.30 | $6.82 | $7.38 | +0.13% |
| May 31 | $6.19 | $6.82 | $7.52 | +0.19% |
| Jun 1 | $6.11 | $6.83 | $7.63 | +0.25% |
| Jun 2 | $6.03 | $6.83 | $7.74 | +0.32% |
| Jun 3 | $5.96 | $6.84 | $7.84 | +0.38% |
| Jun 4 | $5.90 | $6.84 | $7.93 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.90 | $6.84 | $7.93 | +0.44% |
| Week 2 | $5.57 | $6.87 | $8.47 | +0.89% |
| Week 3 | $5.34 | $6.90 | $8.92 | +1.33% |
| Week 4 | $5.16 | $6.93 | $9.32 | +1.78% |
| Week 5 | $5.00 | $6.96 | $9.69 | +2.23% |
| Week 6 | $4.87 | $6.99 | $10.05 | +2.69% |
| Week 7 | $4.75 | $7.02 | $10.39 | +3.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Scilex Holding Company is a healthcare company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia.
It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
Scilex Holding Company is a healthcare company focused on non-opioid pain management products. Its current price is $6.81 and its market capitalization is $47.89M. It ranks 4563 by market cap.
The stock’s near- and long-term price outlook is mixed in the 2026–2050 forecast, with neutral expectations in 2026 and 2027, a bearish turn in 2028, and bullish momentum emerging in 2030 and continuing toward 2040 and 2050. The forecast shows a path to a 2030 average of $9.48, a 2040 average of $11.69, and a 2050 average of $24.09, with corresponding ROIs of 39.1, 71.6, and 253.7 respectively.
A major floor 59.9% below — a decisive break under it would weaken the trend.
The nearest floor, 13.1% below — buyers have tended to step in here.
The nearest ceiling, 63.7% above — a clean break opens room to run.
A major ceiling 93.7% above — clearing it would confirm fresh momentum.
Key SCLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SCLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.25 | Buy | $6.41 | Buy |
| MA 10 | $6.26 | Buy | $6.55 | Buy |
| MA 20 | $7.66 | Sell | $6.93 | Sell |
| MA 50 | $7.22 | Sell | $7.55 | Sell |
| MA 100 | $8.43 | Sell | $8.96 | Sell |
| MA 200 | $13.60 | Sell | $11.55 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.10 | Neutral |
| Stoch RSI (14) | 84.48 | Sell |
| CCI (20) | -36.32 | Neutral |
| Williams %R (14) | -58.02 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | -12.92 | Sell |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 41.98 | Neutral |
| TRIX (15) | -0.50 | Sell |
| Awesome (5,34) | -1.02 | Sell |
| Ultimate (7,14,28) | 52.90 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 6.39 | Buy |
| ADX (14) | 20.97 | Sell |
| ATR (14) | 0.36 | Info |
The near-term technical picture is bearish. RSI14 is 50, while the 50-day and 200-day moving averages stand at $7.22 and $13.60 respectively. The stock trades within a 30-day range of $4.71 to $9.84, with key support at $5.92 and resistance at $11.15.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.92 | $6.81 | $8.84 | 0% | Neutral | |
| $4.59 | $6.37 | $9.58 | -6% | Neutral | |
| $3.76 | $5.55 | $8.87 | -18% | Bearish | |
| $4.95 | $7.68 | $12.87 | +13% | Neutral | |
| $5.83 | $9.48 | $16.52 | +39% | Bullish | |
| $5.13 | $8.72 | $15.72 | +28% | Bullish | |
| $5.08 | $9.01 | $16.74 | +32% | Bullish | |
| $4.67 | $8.61 | $16.45 | +26% | Bullish | |
| $4.06 | $7.80 | $15.27 | +15% | Neutral | |
| $4.02 | $8.03 | $16.08 | +18% | Neutral | |
| $5.26 | $11.69 | $25.70 | +72% | Bullish | |
| $10.84 | $24.09 | $55.40 | +254% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.92 | $6.81 | $8.13 | +0.00% |
| June 2026 | $6.05 | $7.26 | $9.02 | +6.61% |
| July 2026 | $5.91 | $7.21 | $9.19 | -0.65% |
| August 2026 | $5.62 | $6.95 | $9.03 | -3.68% |
| September 2026 | $5.79 | $7.24 | $9.55 | +4.13% |
| October 2026 | $5.88 | $7.42 | $9.93 | +2.54% |
| November 2026 | $5.40 | $6.88 | $9.32 | -7.28% |
| December 2026 | $5.02 | $6.45 | $8.84 | -6.19% |
Click any year to see its month-by-month SCLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Scilex Holding Company's 2026 outlook centres on $6.81, within a $5.92 to $8.84 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, SCLX could reach as high as $9.58, with a base case around $6.37 and support toward $4.59 — roughly -6% from $6.81. Price action looks broadly range-bound.
Expect SCLX to range from $3.76 to $8.87 through 2028. The $5.55 average target implies a -18% move from current prices. That is -13% versus the projected 2027 average. Expect choppier, lower action through this leg of the cycle.
The SCLX price prediction for 2029 points to an average of $7.68 (low $4.95, high $12.87) — a potential gain of +13% on today's $6.81. Price action looks broadly range-bound.
In 2030, SCLX is projected to trade between $5.83 and $16.52, averaging $9.48 — a potential gain of +39% from today's $6.81. That is up +23% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Scilex Holding Company's 2031 outlook centres on $8.72, within a $5.13 to $15.72 range. That is -8% versus the projected 2030 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2032, SCLX could reach as high as $16.74, with a base case around $9.01 and support toward $5.08 — roughly +32% from $6.81. Buyers look set to stay in control over this stretch.
Expect SCLX to range from $4.67 to $16.45 through 2033. The $8.61 average target implies a +26% move from current prices. That is -4% versus the projected 2032 average. Momentum favours further upside here.
The SCLX price prediction for 2034 points to an average of $7.80 (low $4.06, high $15.27) — a potential gain of +15% on today's $6.81. A consolidation phase looks the most probable path here.
In 2035, SCLX is projected to trade between $4.02 and $16.08, averaging $8.03 — a potential gain of +18% from today's $6.81. That is up +3% on the projected 2034 average. Price action looks broadly range-bound.
Scilex Holding Company's 2040 outlook centres on $11.69, within a $5.26 to $25.70 range. That is up +46% on the projected 2035 average. That marks a +72% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, SCLX could reach as high as $55.40, with a base case around $24.09 and support toward $10.84 — roughly +254% from $6.81. Momentum favours further upside here.
Investing $1,000 in SCLX today (≈ 146.842878 SCLX) could be worth
$3,536.8
+$2,536.8 (+254%) by 2050 · US Dollar
Based on the average projected SCLX price of $24.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SCLXwould be worth at today's price.
$1,000 invested in SCLX on May 27, 2025 (≈ 206.185571 SCLX) would be worth
$1,404.12
+$404.12 (+40.4%) today · 1.40× · US Dollar
Based on a SCLX entry price of $4.85 vs. today's $6.81.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.01 | $1,133.11 | +13.3% |
| 1 month ago | $6.88 | $989.83 | -1.0% |
| 3 months ago | $8.12 | $838.67 | -16.1% |
| 6 months ago | $20.36 | $334.48 | -66.6% |
| 1 year ago | $4.85 | $1,404.12 | +40.4% |
| All time (5.0y) ago | $346.5 | $19.65 | -98.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SCLX forecast.
Our base-case forecast reaches $14.00 around 2050.
Implied market cap at $14.00: $98.46M
The multi-year forecast shows a bullish trajectory beginning in the 2030s, with 2030 offering an average price of $9.48 and a max of $16.52 (ROI 39.1) and a bullish sentiment. The 2040 forecast projects an average of $11.69 (ROI 71.6) with continued bullish sentiment, and the 2050 forecast shows an average of $24.09 (ROI 253.7) with bullish sentiment. Early years reveal mixed signals (2026–2029), including neutral and bearish periods, underscoring that these are estimates and not guarantees.
As always, actual results may vary and depend on market conditions and company developments.
Tap a question to reveal the answer.
2030 min $5.83, avg $9.48, max $16.52, ROI 39.1, sentiment BULLISH.
Forecasts show neutral in 2026 and 2027, bearish in 2028, then bullish in 2030 and beyond. The path suggests potential upside but includes negative periods and is not a guarantee.
Yes. The 2030 max forecast is $16.52, with an average of $9.48 and ROI 39.1.
Current price $6.81; market cap $47.89M.
2040 average $11.69 (ROI 71.6), sentiment BULLISH. 2050 average $24.09 (ROI 253.7), sentiment BULLISH.
Scilex Holding Company Community Discussion
0Share your Scilex Holding Company price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.